NASDAQ:PRPH ProPhase Labs Q3 2026 Earnings Date & Estimates $0.0055 0.00 (0.00%) As of 11/9/2026 10:31 AM Eastern ProPhase Labs is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. Research:ProfileEarnings History Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from ProPhase Labs in Q3 2026ProPhase Labs is expected to post earnings of $2.05 per share on revenue of $11.98 million. In the same quarter a year earlier ProPhase Labs reported -$1.60 per share on revenue of $883 thousand. ProPhase Labs last reported on November 19, 2025, posting -$1.60 per share and missing the -$1.10 consensus estimate. ProPhase Labs has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS$2.05Expected Revenue$11.98 millionPrior-Year EPS-$1.60Prior-Year Revenue$883 thousandExpected Revenue Growth+1,256.3%Recent Track RecordLast ReportedQ3 2025Last Quarter EPS-$1.60 (Missed by -$0.50)Last Quarter Revenue$883 thousandEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ3 2025 Earnings ReportQ2 2025 Earnings ReportQ1 2025 Earnings Report ProPhase Labs Q3 2026 Earnings FAQ When does ProPhase Labs report Q3 2026 earnings? ProPhase Labs (NASDAQ:PRPH) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is ProPhase Labs' Q3 2026 earnings call? ProPhase Labs' Q3 2026 earnings conference call is scheduled for Wednesday, November 18, 2026 at 2:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for ProPhase Labs? Analysts expect ProPhase Labs to post earnings of $2.05 per share for Q3 2026. How much revenue is ProPhase Labs expected to report? The consensus revenue estimate for ProPhase Labs is $11.98 million for Q3 2026. ProPhase Labs Earnings HeadlinesProPhase Labs Delays Quarterly SEC FilingAugust 14, 2026 | tipranks.comProPhase Labs Inc.July 16, 2026 | marketwatch.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 10 at 1:00 AM | Weiss Ratings (Ad)ProPhase Labs Announces Immediate Resignation of Board MemberJune 25, 2026 | theglobeandmail.comProPhase Labs Delays Quarterly Financial FilingMay 15, 2026 | tipranks.comProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections PlatformApril 15, 2026 | globenewswire.comSee More ProPhase Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProPhase Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProPhase Labs and other key companies, straight to your email. Email Address About ProPhase LabsProPhase Labs (NASDAQ:PRPH) is a diversified healthcare company focused on diagnostics, genomics, and related healthcare services. Through its operating businesses, the company develops and provides clinical laboratory testing, genetic testing, and data-driven health solutions for consumers, healthcare providers, researchers, and pharmaceutical companies. ProPhase Labs’ activities have included molecular and genomic testing, clinical research support, and precision-health services. Its portfolio has also included Nebula Genomics, a genomics platform designed to provide whole-genome sequencing and enable individuals to manage and share their genetic data. The company has additionally pursued diagnostic products and services addressing infectious diseases and oncology. The company traces its history to the Quigley Corporation, a healthcare products business associated with the Cold-EEZE zinc lozenge brand. It adopted the ProPhase Labs name as its business evolved toward diagnostics and genomics. ProPhase Labs is headquartered in Garden City, New York, and its operations are primarily focused on the U.S. healthcare and research markets, with digital genomics offerings potentially serving customers beyond the United States. Ted Karkus has served as the company’s chief executive officer.View ProPhase Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
